Outlook Therapeutics (OTLK) Stock: Tumbles After LYTENAVA Launch Plans and $51 Million Public Offering

TLDR OTLK stock drops 12.24% after Q3 losses and a $51.1 million public share offering. Outlook Therapeutics posts a $20.3 million Q3 net loss for fiscal year 2026. The company raised about $51.1 million through a large August public offering. Management targets a U.S. LYTENAVA launch before the end of calendar year 2026. LYTENAVA could [...]

The post Outlook Therapeutics (OTLK) Stock: Tumbles After LYTENAVA Launch Plans and $51 Million Public Offering appeared first on Blockonomi.